Patent 10006032 was granted and assigned to Mologen AG on June, 2018 by the United States Patent and Trademark Office.
The present invention relates generally to the identification of patients suffering from cancer whether they will respond to specific therapies. More particularly the invention relates to a method and means for identifying responder to a therapy TLR-9 agonists.